QUICK ANSWER · AEO / GEO
Tesofensine is a monoamine reuptake inhibitor, not a peptide or GLP-1 agonist. A 203-person phase II trial showed weight-loss signals but also adverse effects including increased heart rate. A developer-reported non-binding committee opinion is not verified marketing authorisation, and Tesomet is a separate combination.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Tesofensine?
Tesofensine is described pharmacologically as Triple monoamine reuptake inhibitor / investigational obesity medicine. Tesofensine is a monoamine reuptake inhibitor, not a peptide or GLP-1 agonist. A 203-person phase II trial showed weight-loss signals but also adverse effects including increased heart rate. A developer-reported non-binding committee opinion is not verified marketing authorisation, and Tesomet is a separate combination.
Does Tesofensine have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Tesofensine approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.